62 results about "Tear secretion" patented technology

A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and / or contains said composition for promoting lacrimal secretion is provided.

A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate [UTP], dinucleotides, cytidine 5′-triphosphate [CTP], adenosine 5′-triphosphate [ATP], or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

The invention discloses novel application for Ectoine, namely application of the Ectoine in preparing medicines of treating xerophthalmia. The effective dosage range of the Ectoine is 0.1 to 100 mg / kg of body weight, preferably 8 to 50 mg / kg of the body weight. When in use, the Ectoine can be used independently, or can be combined with medically and pharmaceutically acceptable carriers for use. The inventor of the application makes related experimental research; and the experiment proves that the Ectoine can effectively protect the stability of a tear film, maintain normal tear secretion, and reduce the water evaporation of cornea / conjunctiva, thereby relieving and treating the xerophthalmia.

A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically effective concentration of a muscarinic receptor agonist for promoting lacrimal fluid secretion, which is associated with fewer side effects such as miosis, and a method of promoting lacrimal fluid secretion by administering a percutaneous absorption type ophthalmic preparation containing a muscarinic receptor agonist to the skin surface of the eyelid.

The invention relates to a cyclosporine-containing composition and a preparation method thereof. The compound eye drops are prepared from cyclosporine, anti-inflammatory or antibiotic drugs, a surfactant, a stabilizer, a thickener, an isoosmotic adjusting agent, a pH adjusting agentr and water or oil, the preparation is a mixed suspension agent or an emulsion, and one or two of a high pressure homogenization method and a wet grinding technique is / are combined for use in the preparation method. The cyclosporine compound eye drops have the advantages that the ophthalmic tolerance is excellent, the drug utilization degree is high, the tear secretion of people suffering from xerophthalmia can be effectively improved, the tear film is stabilized, the anti-inflammation function of the anti-inflammatory or antibiotic drugs and the immunoregulation function of cyclosporine can be synergistically exerted, xerophthalmia can be effectively treated, and the compound eye drops have a better treatment effect compared with the separate application of cyclosporine.

A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms and stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the compound include topical administration via a liquid, gel, cream, or as part of a contact lens or a continuous or selective release device; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.

A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

The invention provides a traditional Chinese medicine preparation for treating dry eye diseases, which is prepared from the following raw materials in parts by weight: 6-10 parts of liquorice, 25-35 parts of Chinese wolfberry, 10-20 parts of chrysanthemum, 10-20 parts of radix scrophulariae, 8-15 parts of cassia seeds, 10-30 parts of prepared rhizome of rehmannia, 25-35 parts of radix ophiopogonis, 25-35 parts of astragalus membranaceus, and 25-35 parts of bidens pilosa. The traditional Chinese medicine preparation for treating dry eye diseases can be prepared into any dosage forms by using a pharmaceutically conventional preparation method. The raw materials used in the invention are all pure natural Chinese herbal medicines, therefore, the material taking is convenient and economic, and the preparation method is simple; the curative effect can be improved, especially, and the lacrimal secretion can be increased, thereby relieving the subjective symptoms of patients, and easing the pain; and no toxic or side effect is caused after the preparation is taken for a long time.

A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and / or contains said composition for promoting lacrimal secretion is provided.

The invention discloses an application of novel eye drops in treatment of dry eyes. The novel eye drops contain alpha-MSH; the mass concentration of the alpha-MSH is 10<-4> to 10<-3>mg / ml; the novel eye drops are used for treating the dye eyes; and the optimized mass concentration of the alpha-MSH is 10<-4>mg / ml. By using the novel eye drops, experiment analysis on the breakup time of a tear film (BUT), schirmer test, fluorescein staining, grade and tear ferns is carried out on rats; an overall eyeball of each rat is extracted to be subjected to HE and periodic acid-Schiff (PAS) staining; and the fresh cornea of each rat is extracted to be subjected to real-time quantitative PCR detection of expression levels of interleukin-1beta and tumor necrosis factor-alpha m RNA in corneal tissues, so that the experiments prove that the eye drops containing alpha-MSH are capable of promoting schirmer in rats, prolonging the breakup time of the tear film, stabilizing the tear film, promoting corneal epithelium damage repair and goblet cell quantity repair, and relieving ocular surface inflammation, and are favorable for relieving lesions of the dry eyes.

The invention provides an external traditional Chinese medicinal composition for treating xerophthalmia and a preparation method thereof. The external traditional Chinese medicinal composition for treating the xerophthalmia is prepared from the following raw materials: wolfberry, chrysanthemum, salviae miltiorrhizae, cortex phellodendri, pearl powder, borneol and menthol. The external traditional Chinese medicinal composition for treating the xerophthalmia has the advantages that pathological changes of lacrimal gland tissues of an experimental xerophthalmia mouse, lacrimal glands of which are damaged by injected pingyangmycin, in morphology can be obviously alleviated, quantity of tear fluid can be obviously increased, breakup time of a tear film is prolonged, and quantity of the tear fluid secreted by a normal domestic rabbit can be obviously increased.

Described herein are methods and pharmaceutical formulations for increasing tear production.

This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

The invention provides a medicament for treating a dry eye. The medicament for treating the dry eye is prepared from the following constituents by weight: 5-10 grams of bupleurum, 10-20 grams of white paeony root, 10-15 grams of Chinese angelica, 8-15 grams of dwarf lilyturf tuber, 5-10 grams of mint, 10-15 grams of campanumaea pilosula, 10-30 grams of rehmanniae praeparatum, 5-15 grams of Chinese magnoliavine fruit and 80-100 grams of dextrin. The medicine mainly aims at a patient with the dry eye and can be taken by the patient who is diagnosed with the dry eye in an outpatient department according to following usage and dosage: twice daily, a small bag each time by dissolving with warm water and 15 days for a course of treatment. No contraindication is needed to be noticed by orally taking this medicament. The medicament has effects of soothing the liver, nourishing yin and improving eye sight, human physiological function and immunity, has a certain action of imitating androgen, and can be used for dredging a lachrymal catheter, inhibiting inflammation, restoring tear gland, facilitating tear secretion by the tear gland, enabling dry and burning sensation of the eye to disappear and basically solving the problems of eye discomfort, eye acerbity, lachrymation, light sensitivity and visual deterioration.

The invention discloses a traditional Chinese medicine eye-drop for treating xeroma. The eye-drops is prepared from the following components by weight: 10-50 parts of solomon's seal and 100-200 parts of Houttuynia. The method is as below: first conducting heat reflux extraction, concentration under reduced pressure, alcohol precipitation, bleaching and filtration to obtain a solomon's seal solution; distilling Houttuynia to obtain a Houttuynia aqua aromatica; then mixing the solomon's seal solution and aqua aromatica; adjusting the pH value and osmotic pressure to obtain a light yellow transparent liquid; and then disinfecting and bottling. The solomon's seal and Houttuynia in the traditional Chinese medicine eye-drop have anti-viral and anti-inflammatory effects; the solomon's seal polysaccharide contained in solomon's seal increases tear secretion and promotes healing of the ocular surface; the two components have good effects in improving patient subjective symptoms and increasing tear secretion; the preparation method is simple and low in cost; and the eye-drop is easy to use and can be easily accepted by the patients.

The invention discloses a composition for alleviating dry eyes and visual fatigue. The composition is characterized by comprising an oil phase, an aqueous phase, a sodium hyaluronate solution, a cosolvent and optionally other adjuvants. The use of specific vegetable essential oil instead of a conventional oil phase not only improves the storage stability of the composition, but also serves to further have the effect of treating dry eyes and visual fatigue. In addition, the composition can significantly improve the basal tear secretion and tear film stability of mammals. When the composition is used with a roll, effects of massaging eyes, relieving visual fatigue, moisturizing, resisting oxidation, invigorating blood circulation to eliminate stasis, improving eyesight and the like can be achieved. At the same time, the composition does not have toxic or side effects, and the advantages of portability, capability of being used at any time and in any places, and the like.

The present invention discloses a water-based in-situ gel ophthalmic preparation. Thewater-based in-situ gel ophthalmic preparation comprises the following components: non-steroidal anti-inflammatorydrugs, polysaccharide polymers with in-situ gel characteristics, artificial tears and water, in-situ gel containing the non-steroidal anti-inflammatory drugs and the artificial tears is formed under physiological conditions of eyes, and instantaneous viscosity is increased when the drug solution is dripped into the eyes. The water-based in-situ gel ophthalmic preparation can be used for treating xerophthalmia caused by corneal injury, can supplement lacrimal secretion insufficiency during treatments, increases retention and bioavailability of the drug in the eyes, improves compliance of patients, and reduces stimulation of the drug to eyes of the patients and use frequency of the drug.

The invention relates to a Chinese medicinal preparation, and particularly relates to a Chinese medicinal preparation for treating xerophthalmia due to liver depression and deficiency of yin, belonging to the field of traditional Chinese medicines. The Chinese medicinal preparation is prepared from the following raw materials (Chinese medicinal herbs) in parts by weight: 15-21 parts of nutgrass galingale rhizome, 8-11 parts of white paeony roots, 13-18 parts of gambir plants, 11-15 parts of chrysanthemums, 15-18 parts of roots and stems of smallflower embelia, 10-14 parts of American ginseng, 11-14 parts of rhizoma atractylodis, 9-13 parts of dwarf lilyturf tuber, 5-9 parts of dark plum fruits and 20-25 parts of barbary wolfberry fruits. The Chinese medicinal preparation has the efficacies of soothing the liver, replenishing qi, nourishing yin and moistening eyes. Clinical tests show that the Chinese medicinal preparation is beneficial to effectively increasing the secretion of tears and prolonging the breakup time of a tear film and has a significant clinical effect of treating xerophthalmia due to liver depression and deficiency of yin.

A medical gel for preventing and treating cataract contains the hydrolytic liquid of pearl powder, borneol, Zn, beta-carotene, VE, gel matrix and pharmacologically acceptable carrier. Its preparing process is also disclosed.

The invention relates to a traditional Chinese medicine composition, and in particular relates to a traditional Chinese medicine preparation for treating lung yin deficiency type xerophthalmia. The traditional Chinese medicine preparation is prepared from the following traditional Chinese medicines in parts by weight: 22-26 parts of the root of straight ladybell, 15-20 parts of discolor ludisia herb, 15-20 parts of fragrant solomonseal rhizome, 6-10 parts of climbing nightshade fruit, 5-9 parts of platycodon root, 17-21 parts of chrysanthemum, 15-18 parts of peppermint and 14-19 parts of Chinese mahonia leaf. The traditional Chinese medicine preparation disclosed by the invention has a significant clinical curative effect aiming at treating lung yin deficiency type xerophthalmia, can be used for effectively increasing lacrimal secretion amount and prolonging the breakup time of tear films, has the effects of nourishing yin and moisturizing the lung, removing heat and promoting salivation, and lightly ventilating the lung qi, and ensures that aqueous humor is bred, eyes are moistened and nourished, and eyeballs are lubricated; and the curative effect of curing xerophthalmia can be fundamentally achieved.

The present invention relates to the use of arteether maleate amine (SM934) for the preparation of ophthalmic preparations, and more particularly, to the use of arteether maleate amine for the preparation of ophthalmic preparations for the prevention or treatment of ocular inflammatory injuries caused by insufficient tear secretion.

The invention discloses compound sodium chloride eye drops comprising the components of: sodium chloride, potassium chloride, sodium bicarbonate, hydroxypropylmethyl cellulose, an antiseptic of ethylparaben, and a solvent of water. According to the compound sodium chloride eye drops provided by the invention, a proper amount of hydroxypropylmethyl cellulose is used for regulating the viscosity, and ethylparaben is adopted as the antiseptic, such that the viscosity is appropriate, and a preservative effect is stable. The eye drops have properties similar to those of human body's own tear secretion. With the eye drops, moisture can be supplemented for eyes, eye surface can be moisturized, and a mucinous water-absorbent solution is formed and covered on the surface of eyes, such that eyes can be protected, and patient symptoms can be ameliorated. The eye drops can be used for effectively relieving and treating xerophthalmia.

The invention relates to use of berberine, a stereisomer thereof, pharmaceutically acceptable salt thereof, a pharmaceutically acceptable hydrate thereof or a pharmaceutically acceptable solvate thereof in preparation of drugs, wherein the drugs are used for treating or preventing and inhibiting non-infectious ocular surface inflammation, promoting repairing of ocular surface tissues, increasing conjunctival goblet cells and promoting secretion of tear and / or maintaining the stability of tear films. The berberine locally applied to the ocular surface is capable of inhibiting the non-infectiousocular surface inflammation, promoting the repairing of the ocular surface tissues and increasing the conjunctival goblet cells and has relatively good effects of promoting the secretion of the tearand maintaining the stability of the tear films.

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.